Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Wezenla

WEZENLA 45 mg solution for injection in pre-filled pen WEZENLA 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 55

HOS-151658 · Präparat HOS-100575

In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was explored. There were no indications of an interaction with these concomitantly administered medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the studied population) were treated concomitantly with these medicinal products for at least 90% of the study period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)